Compare GRNQ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRNQ | VRAX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Malaysia | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 1.7M |
| IPO Year | 2014 | 2021 |
| Metric | GRNQ | VRAX |
|---|---|---|
| Price | $2.23 | $0.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 18.2K | ★ 161.6K |
| Earning Date | 04-08-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,673,997.00 | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.55 | N/A |
| 52 Week Low | $0.84 | $0.18 |
| 52 Week High | $2.50 | $1.35 |
| Indicator | GRNQ | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 69.37 | 36.65 |
| Support Level | $1.57 | N/A |
| Resistance Level | $2.50 | $0.25 |
| Average True Range (ATR) | 0.13 | 0.02 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 94.29 | 0.46 |
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.